Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 10708572
• 负责人: David G DeNardo
• 金额: $ 206.5万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-28 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708572
• 关键词: Agonist; Basic Science; Bioinformatics; Biometry; California; Cancer Biology; Cancer Center; Cancer Research Project; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Development; Diagnosis; Disease; Drug resistance; Ensure; Environment; Ethics; Faculty; Fostering; Funding; Genomics; Goals; ITGAM gene; Image; Immunologics; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infrastructure; Institution; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Mentors; Metabolic; Minority; Mission; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Patient Participation; Patient-Focused Outcomes; Patients; Pennsylvania; Quality of life; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Specialized Program of Research Excellence; Stress; Testing; Therapeutic Clinical Trial; Therapeutic Trials; Training; Translational Research; Translations; Universities; Washington; bench-to-bedside translation; cancer genomics; cancer type; career; clinical care; clinical practice; design; drug development; gastrointestinal; immune resistance; improved; improved outcome; innovation; inter-institutional; leukemia; medical schools; multidisciplinary; neoantigen vaccine; novel; novel diagnostics; novel strategies; novel therapeutic intervention; patient population; programs; recruit; resistance mechanism; translational applications; translational cancer research; translational impact; translational potential; treatment strategy

PROJECT SUMMARY The Washington University Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical studies, and our teams leverage individual expertise in immunology, cancer biology, drug development, genomics, and clinical care to develop novel diagnostic and therapeutic approaches for PDAC. This SPORE application includes three research projects, an administrative core (Core A), two shared- resource cores [Biospecimen Core (Core B) and Biostatistics and Bioinformatics Core (Core C)], and developmental research (DRP) and career enhancement (CEP) programs. In collaboration with our External (EAB) and Internal (IAB) Advisory Boards, we intentionally selected projects with the greatest potential to impact the outcome for patients with PDAC. Basic research at WUSM and UPenn has led to the development of the following three research projects, all of which feature innovative investigator-initiated therapeutic trials for PDAC. All projects deemed to have the most potential for translational impact and share an immunologic theme in their approach. This immunologic theme leverages institutional strengths and highlights our team’s expertise and leadership in this field. Thus far, the immunologic and metabolic therapies that have been increasingly successful for controlling other cancer types have not been impactful in PDAC. Our project leaders have made noteworthy contributions to elucidate the mechanisms underlying this immunologic resistance and drug resistance in PDAC and developed several exciting strategies with potential to overcome these obstacles. The three projects in this application are designed to have significant potential to change clinical practice within 5 years. Project 1. Employing CD11b-agonists to render PDAC responsive to immunotherapy Project 2. Mechanisms of Resistance to Neoantigen Vaccines in PDAC Project 3. Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer Our long-term goals are to improve the survival and the quality of life of patients diagnosed with PDAC. To achieve this goal, we will promote institutional and inter-institutional collaborative research, with an emphasis on translation. We anticipate that no singular approach will solve PDAC and fully commit to supporting the development of novel research concepts as well as highly promising young investigators. Our SPORE will provide access to pancreatic cancer–specific resources to facilitate this mission.

项目摘要 华盛顿大学胰腺癌卓越研究专业计划（SPORE）是一个 高度转化的癌症研究计划完全集中在疾病的最致命的形式，胰腺癌 导管腺癌（PDAC）。我们优秀的调查人员在基础和 临床研究，我们的团队利用免疫学，癌症生物学，药物开发， 基因组学和临床护理，以开发PDAC的新诊断和治疗方法。 此SPORE应用程序包括三个研究项目，一个管理核心（核心A），两个共享- 资源核心[生物标本核心（核心B）和生物统计学和生物信息学核心（核心C）]，以及 发展研究（DRP）和职业发展（CEP）计划。与外部合作 (EAB)和内部（IAB）咨询委员会，我们有意选择最有可能产生影响的项目 PDAC患者的结局。WUSM和宾夕法尼亚大学的基础研究导致了 接下来的三个研究项目，所有这些都具有创新的药物启动的PDAC治疗试验。 所有被认为最有可能产生转化影响的项目，并在其研究中共享一个免疫学主题。 approach.这个免疫学主题利用了机构的优势，突出了我们团队的专业知识， 领导在这个领域。到目前为止，越来越成功的免疫和代谢疗法 用于控制其他癌症类型在PDAC中没有影响。我们的项目负责人做出了值得注意的 有助于阐明PDAC中这种免疫耐药性和耐药性的机制 并制定了几个令人兴奋的战略，有可能克服这些障碍。这三个项目 应用程序的设计具有在5年内改变临床实践的巨大潜力。 项目1。使用CD 11b-激动剂使PDAC对免疫疗法有反应 项目2. PDAC对新抗原疫苗的耐药机制 项目3。靶向应激诱导的MK2作为胰腺癌治疗的新策略 我们的长期目标是提高PDAC患者的生存率和生活质量。到 为了实现这一目标，我们将促进机构和机构间的合作研究，重点是 翻译.我们预计，没有单一的方法将解决PDAC，并完全致力于支持 发展新的研究概念以及非常有前途的年轻研究人员。我们的SPORE将 提供获得胰腺癌特定资源的途径，以促进这一使命。